High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
7.12B
+10.61%
4.392
+9.52%
6.32B
+7.74%
3.063
+7.86%
6.54B
+8.64%
3.477
+11.1%
Estimates Revision
The market is revising Upward the revenue expectations for Stryker Corporation (SYK) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -5.58%.
Revenue Estimates for FY2025
Revise Upward
+0.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.38%
In Past 3 Month
Stock Price
Go Down
-5.58%
In Past 3 Month
15 Analyst Rating
Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 430.60 USD with a low forecast of 392.00 USD and a high forecast of 455.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 360.310
Low
392.00
Averages
430.60
High
455.00
Current: 360.310
Low
392.00
Averages
430.60
High
455.00
Truist
Richard Newitter
Hold
maintain
$392 -> $400
2025-11-14
New
Reason
Truist
Richard Newitter
Price Target
$392 -> $400
2025-11-14
New
maintain
Hold
Reason
Truist analyst Richard Newitter raised the firm's price target on Stryker to $400 from $392 and keeps a Hold rating on the shares. The company's Investor Day showcased why Stryker should remain one of the higher quality large-cap MedTechs with "muscle" and continue delivering annual operating leverage, the analyst tells investors in a research note. Truist adds however that it remains in neutral as the firm prefers large-caps with faster earnings and revenue growth profiles.
Wells Fargo
Overweight
maintain
$452 -> $456
2025-11-14
New
Reason
Wells Fargo
Price Target
$452 -> $456
2025-11-14
New
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Stryker to $456 from $452 and keeps an Overweight rating on the shares. The firm notes the company's 2025 investor meeting highlighted the potential for sustained 10% organic topline growth and double-digit EPS growth. Margin target of 150bps next 3 years was slightly better than expected. Key pipeline updates include Mako RPS hand-held robot, Wells adds.
BTIG
BTIG
Buy
downgrade
$122 -> $112
2025-11-05
Reason
BTIG
BTIG
Price Target
$122 -> $112
2025-11-05
downgrade
Buy
Reason
BTIG lowered the firm's price target on Zimmer Biomet (ZBH) to $112 from $122 and keeps a Buy rating on the shares following disappointing Q3 results. The firm notes that relative to peers, Zimmer Knee growth fell below Stryker (SYK) but above Johnson & Johnson (JNJ) while Hips were softest among the 3. There is no way to spin it, results were disappointing relative to expectations as Zimmer came off a strong Q2 and into the print investor enthusiasm was growing from an easier comp and new product launches, says BTIG.
Truist
Hold
downgrade
$407 -> $392
2025-11-03
Reason
Truist
Price Target
$407 -> $392
2025-11-03
downgrade
Hold
Reason
Truist lowered the firm's price target on Stryker to $392 from $407 and keeps a Hold rating on the shares. The company delivered a small revenue beat with mixed quality earnings upside that was driven by non-op items and tax, which offset a slight operating margin miss, the analyst tells investors in a research note.
Evercore ISI
Outperform
maintain
$410 -> $405
2025-10-31
Reason
Evercore ISI
Price Target
$410 -> $405
2025-10-31
maintain
Outperform
Reason
Evercore ISI lowered the firm's price target on Stryker to $405 from $410 and keeps an Outperform rating on the shares. Stryker's Q3 performance was solid with a 9.5% organic growth, slightly topping Wall Street estimates, mainly driven by Orthopedics' strong showing, the analyst tells investors in a research note. The firm noted that MedSurg and NeuroTech held steady, though Endoscopy and Medical lagged a bit behind expectations.
Truist
Richard Newitter
Hold
downgrade
$407 -> $392
2025-10-31
Reason
Truist
Richard Newitter
Price Target
$407 -> $392
2025-10-31
downgrade
Hold
Reason
Truist analyst Richard Newitter lowered the firm's price target on Stryker to $392 from $407 and keeps a Hold rating on the shares following Q3 results with "mixed quality" earnings upside. Some key organizational revenue drivers fell short, but hips/knees picked up and record Mako placements could be suggestive of Mako 4 gaining steam, Truist told investors in a research note. The firm's estimates inch upwards, and with the November 13 investor day coming up, Truist said it will get a sense of management's long-term targets and whether there could be faster growth prospects to support a higher multiple.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Stryker Corp (SYK.N) is 24.99, compared to its 5-year average forward P/E of 26.35. For a more detailed relative valuation and DCF analysis to assess Stryker Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
26.35
Current PE
24.99
Overvalued PE
28.46
Undervalued PE
24.24
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
21.38
Current EV/EBITDA
20.34
Overvalued EV/EBITDA
22.89
Undervalued EV/EBITDA
19.87
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
9.41
Current PS
362.22
Overvalued PS
47.31
Undervalued PS
-28.48
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 143.24% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 119.77% over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased712.5%over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 143.24% over the last month.
Sold
Bought
SYK News & Events
Events Timeline
(ET)
2025-10-30
16:13:49
Stryker projects FY25 adjusted EPS between $13.50 and $13.60, surpassing consensus of $13.49
2025-10-30
16:13:09
Stryker announces Q3 adjusted earnings per share of $3.19, surpassing consensus estimate of $3.13.
2025-10-30
14:00:28
Prominent Companies Set to Report After Market Close
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/642bcf6cbfd4cbf48dcf8f4c5efc2b665fc4e391d5df94332ef5fe9696c8076b.png)
Preview
2.0
11-17BenzingaReasons Stryker Stock Could Experience an Extended Slowdown
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/b225a6cb32670bac426a2eb87fd72bb98b0308b99c165c4a2e76f6ef5c0d2e23.png)
Preview
6.0
11-14BenzingaNeedham Affirms Buy Rating on Stryker, Keeps $448 Price Target Intact
Preview
6.0
11-14BenzingaBTIG Affirms Buy Rating for Stryker, Keeps Price Target at $410
Sign Up For More News
People Also Watch
FAQ
What is Stryker Corp (SYK) stock price today?
What is Stryker Corp (SYK)'s business?
What is the price predicton of SYK Stock?
What is Stryker Corp (SYK)'s revenue for the last quarter?
What is Stryker Corp (SYK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Stryker Corp (SYK)'s fundamentals?
How many employees does Stryker Corp (SYK). have?